Evaluating cosmetic outcomes of whole breast irradiation with a boost for early-stage breast cancer

Patient-Reported Outcomes and Cosmesis Following Five Fraction Whole Breast Irradiation With Simultaneous Integrated Boost

NA · University of Wisconsin, Madison · NCT06295744

This study is testing if a new type of radiation therapy can improve the appearance of the breast and overall experience for women with early-stage breast cancer after surgery.

Quick facts

PhaseNA
Study typeInterventional
Enrollment50 (estimated)
Ages18 Years and up
SexFemale
SponsorUniversity of Wisconsin, Madison (other)
Drugs / interventionschemotherapy, radiation
Locations1 site (Madison, Wisconsin)
Trial IDNCT06295744 on ClinicalTrials.gov

What this trial studies

This study evaluates the cosmetic outcomes, patient-reported outcome measures (PROMs), and toxicities in women with early-stage breast cancer undergoing ultra-short whole breast irradiation (WBI) therapy combined with a simultaneous integrated boost (SIB). A total of 50 participants will be enrolled, all of whom will have non-metastatic invasive breast cancer or ductal carcinoma in situ (DCIS). Participants will undergo breast-conserving surgery followed by adjuvant radiation therapy, with assessments conducted at multiple follow-up points over a period of 60 months. The study aims to provide insights into the effectiveness and safety of this treatment approach.

Who should consider this trial

Good fit: Ideal candidates are women aged 18 and older with early-stage invasive breast cancer or DCIS who are undergoing breast-conserving surgery and are eligible for whole breast irradiation with a tumor bed boost.

Not a fit: Patients who have undergone mastectomy or have metastatic disease will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could improve cosmetic outcomes and quality of life for women undergoing breast cancer treatment.

How similar studies have performed: Other studies have shown promising results with similar approaches to whole breast irradiation, indicating potential for success in this study.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Ability to understand and the willingness to sign a written informed consent document
* Histologically confirmed early stage (stage T1-T2) invasive carcinoma of the breast or DCIS
* Breast conserving surgery with negative margins and negative nodes (surgical axillary staging not mandatory), stage N0 or Nx
* Treatment plan should include breast conserving surgery and adjuvant whole breast irradiation (WBI) therapy delivered with 3D-CRT or IMRT techniques
* Treatment plan includes breast tumor bed boost
* Willingness to comply with all study procedures and be available for the duration of the study

Exclusion Criteria:

* Mastectomy of ipsilateral breast
* Lack of histologic diagnosis
* Histologic involvement of the axillary or regional nodes or metastatic disease
* Accelerated partial breast irradiation treatment plan
* Previous history of non-breast malignancy diagnosed in the past 5 years except for basal or squamous cell cancer of the skin
* Previous history of chest radiation therapy
* Previous history of ipsilateral breast cancer
* Concurrent cytotoxic chemotherapy
* Active connective tissue disease including scleroderma
* Inability or unwillingness to return for required follow up visit

Where this trial is running

Madison, Wisconsin

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Early-stage Breast Cancer, Cosmesis, Simultaneous Integrated Boost, Whole Breast Irradiation

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.